Article thumbnail
Location of Repository

Flowchart of subject recruitments for these experimental trials.

By Michael Donahoe (755892), Vincent G. Valentine (355606), Nydia Chien (755893), Kevin F. Gibson (172460), Jay S. Raval (755894), Melissa Saul (64923), Jianmin Xue (355591), Yingze Zhang (81580) and Steven R. Duncan (355610)

Abstract

<p>Original Regimen denotes the first series of subjects who were treated with the initial, relatively more conservative regimen (#1–7). Augmented Regimen denotes the most recent four subjects (#8–11) who received a more aggressive therapeutic course, based on interval results in the first cohort (see text for details). TPE = therapeutic plasma exchange; IVIG = intravenous immunoglobulin; * denotes oral consent of patients, under auspices of innovative clinical practice, that were given by these patients after being fully informed of potential risks and yet-unproven efficiencies of the novel treatments.</p

Topics: Biological Sciences, ivig, tpe, medications.ConclusionThis pilot trial, therapy, plasma MMP 7 levels, Idiopathic Pulmonary Fibrosis BackgroundSevere, elisa, trial subjects, Autoantibodie, IPF progression, autoantibody reduction treatments, ae, nct
Year: 2015
DOI identifier: 10.1371/journal.pone.0127771.g001
OAI identifier: oai:figshare.com:article/1451498
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://figshare.com/articles/... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.